Rivastigmine transdermal patch + placebo patch
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium
Trial Timeline
Jun 1, 2011 → Feb 1, 2016
NCT ID
NCT01487317About Rivastigmine transdermal patch + placebo patch
Rivastigmine transdermal patch + placebo patch is a phase 3 stage product being developed by Novartis for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT01487317. Target conditions include Delirium.
What happened to similar drugs?
5 of 12 similar drugs in Delirium were approved
Approved (5) Terminated (3) Active (5)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01487317 | Phase 3 | Completed |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 42 |
| Suvorexant + Placebo | Merck | Phase 3 | 40 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 35 |
| Rivastigmine + Placebo | Novartis | Approved | 35 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 40 |
| Rivastigmine Patch | Novartis | Approved | 43 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Parecoxib | Pfizer | Approved | 39 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 32 |
| Pregabalin | Pfizer | Phase 3 | 40 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 47 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 26 |
| Dexmedetomidine + Saline placebo | Pfizer | Phase 2/3 | 38 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 39 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 37 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 40 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 17 |